Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales ...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.

Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of ...

TXG AZTA EVO BLFS NAGE ADPT Company Name 10x Genomics, Inc. Azenta, Inc. Evotec SE BioLife Solutions, Inc. Niagen Bioscience, Inc. Adaptive Biotechnologies Corporation Sector Health Care Health ...

Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors in 10x Genomics Inc (Symbol: TXG) saw new options become available this week, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...